Immunogenicity of Salmonella typhi Ty21a vaccine for young children
- PMID: 1937790
- PMCID: PMC259034
- DOI: 10.1128/iai.59.11.4291-4293.1991
Immunogenicity of Salmonella typhi Ty21a vaccine for young children
Abstract
An attenuated Salmonella typhi Ty21a vaccine was administered to 18 infants and toddlers (less than or equal to 24 months old) to determine its safety and immunogenicity. The vaccination (10(9) CFU per dose, three doses) was well tolerated. However, after the vaccination there was no evidence of a humoral or cellular immune response to S. typhi. The vaccine used was known to be immunogenic for older children and adults. The results support the view that the immunogenicity of Ty21a is age dependent.
Similar articles
-
Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers.Vaccine. 2004 Jun 2;22(17-18):2273-7. doi: 10.1016/j.vaccine.2003.11.020. Vaccine. 2004. PMID: 15149786 Clinical Trial.
-
Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies.J Infect Dis. 1991 Apr;163(4):901-4. doi: 10.1093/infdis/163.4.901. J Infect Dis. 1991. PMID: 2010645
-
Demonstration of specific IgA in human feces after immunization with live Ty21a Salmonella typhi vaccine.J Infect Dis. 1985 Mar;151(3):482-4. doi: 10.1093/infdis/151.3.482. J Infect Dis. 1985. PMID: 3882850
-
M-01ZH09, an oral live attenuated Salmonella enterica serovar Typhi vaccine for the prevention of typhoid fever.Curr Opin Mol Ther. 2009 Oct;11(5):565-71. Curr Opin Mol Ther. 2009. PMID: 19806505 Review.
-
Experience with Salmonella typhi Vi capsular polysaccharide vaccine.Eur J Clin Microbiol Infect Dis. 1999 Sep;18(9):609-20. doi: 10.1007/s100960050361. Eur J Clin Microbiol Infect Dis. 1999. PMID: 10534182 Review.
Cited by
-
Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit.Infect Immun. 1992 Oct;60(10):4260-8. doi: 10.1128/iai.60.10.4260-4268.1992. Infect Immun. 1992. PMID: 1398937 Free PMC article.
-
Vaccination against typhoid fever: present status.Bull World Health Organ. 1994;72(6):957-71. Bull World Health Organ. 1994. PMID: 7867143 Free PMC article. Review.
-
Vaccines against invasive Salmonella disease: current status and future directions.Hum Vaccin Immunother. 2014;10(6):1478-93. doi: 10.4161/hv.29054. Epub 2014 May 7. Hum Vaccin Immunother. 2014. PMID: 24804797 Free PMC article. Review.
-
Vaccines for preventing typhoid fever.Cochrane Database Syst Rev. 2018 May 31;5(5):CD001261. doi: 10.1002/14651858.CD001261.pub4. Cochrane Database Syst Rev. 2018. PMID: 29851031 Free PMC article.
-
Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodies.Vaccine. 2010 Aug 23;28(37):6065-75. doi: 10.1016/j.vaccine.2010.06.089. Epub 2010 Jul 7. Vaccine. 2010. PMID: 20619377 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources